BackSigilon Therapeutics Overview

Sigilon Therapeutics Research & Development

Get informed when a big investor buys or sells

+ Follow

Quarterly R&D Expenses

$7.45M
37.27% YoY

As of Jun 30, 2023

Annual R&D Expenses (TTM)

$29.37M
46.44% YoY

Trailing 12 months ending Jun 30, 2023

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Sigilon Therapeutics (SGTX) FAQ

Stockcircle tracks research & development for Sigilon Therapeutics (SGTX), including historical charts and peer comparisons when data is available. Check back as new filings are published, or open the stock overview for a broader fundamental snapshot.

This Research & Development page is built for Sigilon Therapeutics's historical R&D spending trend and peer context. When enough reporting periods are on file, the charts below visualize how the metric has moved over time.

Use R&D spending as one input alongside growth, profitability, valuation, and ownership activity. Stockcircle links related metric pages and the main SGTX overview so you can move from this figure to the surrounding analysis quickly.